| 5.1 Primary: BPD symptom severity (continuous) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.1.1 End of treatment |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.08 [‐4.99, ‐1.17] |
| 5.1.2 0‐6 months follow‐up |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.02 [‐4.23, 0.19] |
| 5.2 Primary: BPD symptom severity (dichotomous), at above 12 months follow‐up |
1 |
76 |
Risk Ratio (IV, Fixed, 95% CI) |
0.91 [0.56, 1.48] |
| 5.3 Primary: self‐harm (continuous) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.3.1 End of treatment |
1 |
28 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.03 [‐5.68, ‐0.38] |
| 5.3.2 0‐6 months follow‐up |
1 |
28 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.71 [‐11.60, 2.18] |
| 5.4 Primary: self‐harm (dichotomous), at end of treatment |
1 |
|
Risk Ratio (IV, Fixed, 95% CI) |
Subtotals only |
| 5.5 Primary: suicide‐related outcomes (continuous) |
2 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 5.5.1 End of treatment |
2 |
104 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.47 [‐1.02, 0.08] |
| 5.5.2 0‐6 months follow‐up |
1 |
28 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.45 [‐1.20, 0.31] |
| 5.5.3 6‐12 months follow‐up |
1 |
76 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.44 [‐0.89, 0.02] |
| 5.5.4 Above 12 months follow‐up |
1 |
76 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.31 [‐0.77, 0.14] |
| 5.6 Primary: psychosocial functioning (continuous) |
2 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 5.6.1 End of treatment |
1 |
99 |
Std. Mean Difference (IV, Random, 95% CI) |
0.00 [‐0.39, 0.39] |
| 5.6.2 6‐12 months follow‐up |
1 |
90 |
Std. Mean Difference (IV, Random, 95% CI) |
0.13 [‐0.28, 0.55] |
| 5.6.3 Above 12 months follow‐up |
2 |
209 |
Std. Mean Difference (IV, Random, 95% CI) |
0.04 [‐0.36, 0.43] |
| 5.7 Secondary: interpersonal problems (continuous) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.7.1 End of treatment |
1 |
99 |
Mean Difference (IV, Fixed, 95% CI) |
5.40 [‐3.70, 14.50] |
| 5.7.2 6‐12 months follow‐up |
1 |
99 |
Mean Difference (IV, Fixed, 95% CI) |
0.30 [‐9.17, 9.77] |
| 5.7.3 Above 12 months follow‐up |
1 |
76 |
Mean Difference (IV, Fixed, 95% CI) |
11.70 [0.72, 22.68] |
| 5.8 Secondary: dissociation and psychotic‐like symptoms (continuous) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.8.1 End of treatment |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.30 [‐8.84, 4.24] |
| 5.8.2 0‐6 months follow‐up |
1 |
26 |
Mean Difference (IV, Fixed, 95% CI) |
‐13.40 [‐24.49, ‐2.31] |
| 5.9 Secondary: depression (continuous) |
5 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 5.9.1 End of treatment |
5 |
314 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.21 [‐0.77, 0.35] |
| 5.9.2 0‐6 months follow‐up |
1 |
26 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.96 [‐1.78, ‐0.14] |
| 5.9.3 6‐12 months follow‐up |
1 |
99 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.29 [‐0.69, 0.11] |
| 5.9.4 Above 12 months follow‐up |
2 |
197 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.15 [‐0.43, 0.13] |
| 5.10 Secondary: attrition (dichotomous), at end of treatment |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 5.11 Secondary: adverse effects (dichotomous), at end of treatment |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 5.11.1 Non‐serious adverse effects |
1 |
306 |
Risk Ratio (M‐H, Random, 95% CI) |
0.92 [0.45, 1.88] |
| 5.11.2 Serious adverse effects |
2 |
326 |
Risk Ratio (M‐H, Random, 95% CI) |
2.65 [0.31, 22.93] |
